Revolutionizing Antiseizure Medication Discovery

Strategic Insights -

Despite over 30 marketed antiseizure medications (ASMs), approximately 30 percent of epilepsy patients continue to experience seizures that are not completely managed by available therapies. The urgent need to revamp therapy discovery strategies has led to a pivotal shift in the approach to treating drug-resistant epilepsy. Recent advances in genetic sequencing technologies have facilitated the strategic use of syndrome-specific epilepsy models to discover novel compounds, paving the way for next-generation drug discovery for epilepsy.

Key Takeaways:

  • Kindling-induced epileptogenesis is characterized by significant behavioral and neurological changes, including substantial changes in activity and a decrease in risk assessment behaviors.
  • The current challenges in antiseizure medication discovery highlight the critical need to innovate discovery strategies to better address the needs of patients with drug-resistant epilepsy and developmental and epileptic encephalopathies.
  • Syndrome-specific models are becoming increasingly important in the development of innovative treatments for epilepsy, offering opportunities to better address the pressing medical needs of individuals with treatment-resistant epilepsy.
  • Integrating syndrome-specific models into early-stage development processes is expected to improve the efficacy and translatability of preclinical epilepsy research.
  • Speakers Melissa Barker-Haliski, Leo Silenieks, and Neil Upton will discuss the innovative approaches and cutting-edge research in next-generation drug discovery for epilepsy during the upcoming webinar on September 23, 2024.
  • The webinar aims to provide attendees with insights into cutting-edge discovery strategies for drug-resistant epilepsy, including the role of syndrome-specific models, recent research on kindling-induced epileptogenesis, and strategies to enhance preclinical testing.

Statistics:

  • Approximately 30 percent of epilepsy patients experience seizures that are not completely managed by available therapies.
  • Over 30 marketed ASMs are available, but a significant proportion of patients continue to suffer from pharmacoresistant epilepsy.
  • Kindling-induced epileptogenesis results in substantial changes in activity levels and a decrease in risk assessment behaviors in mice.
  • Genetic sequencing technologies have facilitated the strategic use of syndrome-specific epilepsy models to discover novel compounds for treating drug-resistant epilepsy.

Sources:

  • Xtalks
  • PR Newswire-PRWeb